Biotron Limited · ASX:BIT

Biotron — Biotech Showcase 2017

21 slides from Biotron's conference presentation, January 2017

  1. Slide 1: Biotron Limited Update – January 2017

    BIOTRON LIMITED (ASX:BIT) Update – January 2017

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presenta,on may contain forward-looking statements with respect to the financial condi,on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec,ves of its management. These statements are statements that

  3. Slide 3: Biotron Limited

    Biotron Limited • Spun out from John Cur,n School of Medical Research at the Australian Na,onal University in 1999 • Listed on ASX in Jan 2001 (ASX:BIT) • Headquartered in Sydney, Australia • Directors • Michael Hoy Chairman • Michelle Miller CEO & Managing Director; ex-Johnson & Johnson Research; e

  4. Slide 4: Biotron – Leader in Viroporin-Targeting Drug Development

    Biotron – Leader in Viroporin-TargeHng Drug Development • Biotron’s core exper,se is based on design and development of a new class of an,viral drugs targe,ng viral ion channel proteins (viroporins) • Viroporins are present in broad range of viruses: • Influenza (M2), HIV-1 (Vpu), Hep C (p7), Dengue

  5. Slide 5: Viroporins

    Viroporins • Small hydrophobic proteins with ion channel ac,vity • Form hydrophilic pores in host cell membranes • Key stages of the viral cycle such as virus uncoa,ng, transport and matura,on are ion-influenced processes in many viral species • Crucial for viral pathogenicity due to involvement in v

  6. Slide 6: Biotron's Core Technology

    Biotron’s Core Technology OTHER “HITS” IN LIBRARY include: Designed library of Compounds screened in - Influenza A and B compounds to target proprietary assay set up for - Coronaviruses viroporins: each virus target e.g. HIV-1 - Including SARS Vpu; HCV p7; Influenza M2; IniHally >250 compounds - Epste

  7. Slide 7: BIT225 Snapshot

    BIT225 Snapshot - First - inPrepared class drugbased and new ondrug target above aoerforthe treatment AugustofBoard HIV-1mee,ng and Hepa,,s C virus (HCV) - Seven clinical trials - Guided completed; the wording of another is fully recruited the prospectus drao andwiththe data expected use 1Q16 of pro

  8. Slide 8: BIT225 – First of a New Class of HCV DAA Drugs

    BIT225 – First of a New Class of HCV DAA Drugs ü Novel, oral, small molecule compound POLYMERASE/PROTEASE INHIBITORS e.g. Sofosbuvir/Simeprevir ü Only one of its class (p7 inhibitor) in clinical trials ü Inhibits viral assembly and infec,vity BIT225 - ASSEMBLY/ BUDDING INHIBITOR ü Pan-genotype ac,vi

  9. Slide 9: HIV-1: Towards a Cure

    HIV-1: Towards a Cure • Over 1.1 million people living with HIV-1 in the USA, with 1 in 6 unaware of diagnosis • US$11.9 bn sales in US, Europe and Japan in 2013; expected to grow to US$16.8 bn by 2020 • HIV-1 pa,ents need to stay on an,retroviral drugs (ART) to keep virus levels under control • Lon

  10. Slide 10: HIV-1 Reservoirs

    HIV-1 Reservoirs • HIV-1 remains hidden in reservoirs, leading to chronic, life-long infec,on – Invisible to body’s immune defenses – Not sensi,ve to an,-HIV-1 drugs • Eradica,on will require mul,ple approaches; approaches include: – An,-latency agents for latently-infected T cells – Drugs to modify

  11. Slide 11: BIT225 Targets HIV-1 in Reservoir Cells

    BIT225 Targets HIV-1 in Reservoir Cells • BIT225 inhibits assembly and budding of new virus in macrophages • Phase 2a trial (004) demonstrated that BIT225 can reduce HIV-1 levels in macrophage cells in vivo, paralleling in vitro studies (Wilkinson et al, J An,microb Chemother. 2015 Nov 29. pii: dkv3

  12. Slide 12: BIT225 – Proven Clinical Activity Against HIV-1

    BIT225 – Proven Clinical AcHvity Against HIV-1 16 • BIT225-004: Phase 1b/2a randomised, placebo controlled, double-blind trial Placebo 14 BIT225 HIV-1 Replica,on (pg/200uL) – 21 pa,ents, HIV-1 posi,ve, treatment-naïve; 10 days dosing with BIT225 12 (monotherapy) 10 • Results demonstrated that: 8 1.

  13. Slide 13: HIV-1 Viral Dynamics

    HIV-1 Viral Dynamics BIT225-009 Hu-Mouse ATI Slide 13

  14. Slide 14: Current HIV-1 Program Trials

    Current HIV-1 Program Trials • Phase 2 trial an,cipated to commence early 2017 • 12 weeks BIT225 in combina,on with cART • Expected outcome(s) – Impact on kine7cs of viral load decay in combina7on with ART indica7ng impact on underlying viral reservoir, also impact on immune ac7va7on • Headline data

  15. Slide 15: Unlocking Value in Compound Library

    Unlocking Value in Compound Library • Renewed industry interest in targe,ng viral diseases including • Respiratory syncy,al virus (RSV) • Hepa,,s B virus • Tropical diseases including Dengue • Influenza (in par,cular drug resistant strains) • Ebola and MERS-CoV outbreaks have caused public health iss

  16. Slide 16: Compound Library is Rich Source of Hits

    Compound Library is Rich Source of Hits X-axis: compound ID Y-axis: virus Z-axis: strength of hit Slide 16

  17. Slide 17: Dengue Virus Program

    Dengue Virus Program • 2.5 billion people (40% world popula,on) live in areas at risk of Dengue • ~100 million people infected yearly • A leading cause of illness and death in tropics and subtropics • Transmission is by mosquito; most preven,on programs target the vector • No approved Dengue-specific

  18. Slide 18: Hepatitis B Virus

    HepaHHs B Virus • Limited screening of Biotron compound library has generated interes,ng data • Hits iden,fied • Very experienced scien,fic advisory and opera,onal team in place for HBV • Seeking collabora,on to explore hits and develop program Slide 18

  19. Slide 19: Summary I

    Summary I • Unique core exper,se against novel viral targets • Demonstrated proof of concept of successful targe,ng of viroporins with BIT225 • BIT225 is a novel approach with demonstrated promising efficacy in Phase 2a/2 clinical trials • HCV and HIV-1 are high growth, mul,-billion dollar markets • T

  20. Slide 20: Summary II

    Summary II • Technology core is an an,viral plakorm with new class of small molecules with broad range of ac,vi,es • Extending earlier stage programs for other key viruses: • Developing leads for programs including Dengue and HBV • Iden,fying hits for other viruses including RSV, Zika, BK, and other

  21. Slide 21: Dr Michelle Miller, Managing Director

    Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au

Biotron — Biotech Showcase 2017 on 6ix